Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of switching from recombinant human erythropoietin to GSK1278863 in hemodialysis-dependent chronic kidney disease anemia
2012-004049-34Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of daprodustat in anemia of renal disease and chronic kidney disease (CKD) (2 arms), sponsored by GSK. Primary endpoint: Modeled hemoglobin change from baseline over 4 weeks of treatment. Started Oct 2012; status: completed.
02
Drugs
daprodustat
03
Conditions
anemia of renal diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-004049-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004049-34.